Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment

Bone Marrow Transplantation

Volumn 33, Issue 2, 2004, Pages 237-242

  Kim, Y J ^a   Kim, D W ^a,b   Lee, S ^a   Kim, Y L ^a   Hwang, J Y ^a   Park, Y H ^a   Kim, H J ^a   Lee, J W ^a   Min, W S ^a   Kim, C C ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Chronic myelogenous leukemia; Clonal evolution; Hematopoietic stem cell transplantation; Imatinib mesylate; Relapse

Indexed keywords

ALPHA INTERFERON; IMATINIB;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HUMAN; LEUKEMIA REMISSION; MALE; MOLECULAR EVOLUTION; MYALGIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS; CLONE CELLS; COMBINED MODALITY THERAPY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PIPERAZINES; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION;

EID: 0842280769     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704332     Document Type: Article

References (33)

1. Gratwohl A, Hermans J, Niederwieser D et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993; 12: 509-516.
2. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17: S5-S6.
3. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
4. Dazzi F, Szydlo RM, Cross NC et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712-2716.
5. Keil F, Haas OA, Fritsch G et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997; 89: 3113-3117.
6. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988; 319: 990-998.
7. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.
8. Talpaz M, Silver RT, Druker BJ et al. Imatinib mesylate induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
9. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
10. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
11. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib mesylate induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
12. Wassmann B, Klein SA, Scheuring U et al. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 721-724.
13. Olavarria E, Craddock C, Dazzi F et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99: 3861-3862.
14. Kantarjian HM, O'Brien S, Cortes JE et al. Imatinib mesylate treatment for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590-1595.
15. McCann SR. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML. Blood 2003; 101: 1200-1201.
16. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 1994; 84: 4368-4373.
17. Majlis A, Smith TL, Talpaz M et al. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996; 14: 196-203.
18. Kantarjian HM, Keating MJ, Estey EH et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 1992; 10: 772-778.
19. Kantarjian HM, Dixon D, Keating MJ et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441-1446.
20. Lee YK, Lee DW, Kim YL et al. Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood. Int J Hematol 2002; 76: 180-185.
21. Kim YJ, Kim DW, Lee S et al. Comprehensive comparison of FISH, RT-PCR, and Q-RT-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Eur J Haematol 2002; 68: 272-280.
22. Lee S, Kim DW, Cho B et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003; 120: 145-153.
23. Kim YL, Hwang JY, Kim YJ et al. Allele frequencies of 15 STR loci using AmpF/STR Identifiler kit in a Korean population. Forensic Sci Int 2003; 136: 92-95.
24. O'Dwyer ME, Mauro MJ, Kurilik G et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002; 100: 1628-1633.
25. Cortes JE, Talpaz M, Giles F et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate treatment. Blood 2003; 101: 3794-3800.
26. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib mesylate (STI571) treatment. Leukemia 2002; 16: 2190-2196.
27. da Silva MA, Heerema NA, Lowe LR et al. Cytogenetic patterns following bone marrow transplantation for chronic granulocytic leukemia. Cancer Genet Cytogenet 1988; 36: 35-44.
28. Calabrese G, Di Bartolomeo P, Stuppia L et al. Cytogenetics in patients with chronic myelogenous leukemia treated with bone marrow transplantation. Cancer Genet Cytogenet 1989; 41: 49-59.
29. Sessarego M, Frassoni F, Defferrari R et al. Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation. Cancer Genet Cytogenet 1991; 57: 69-78.
30. Cortes JE, Giles F, O'Brien S et al. Result of high-dose imatinib mesylate in patients with philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon. Blood 2003; 102: 83-86.
31. Kantarjian HM, Talpaz M, O'Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose treatment in patients with chronic myelogenous leukemia. Blood 2003; 101: 473-475.
32. Soiffer RJ, Galinsky I, DeAngelo D et al. Imatinib mesylate (Gleevec) for disease relapse following allogeneic bone marrow transplantation (abstract). Blood 2001; 98: 400.
33. van Rhee F, Savage D, Blackwell J et al. Adoptive immunotreatment for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998; 21: 1055-1061.